KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) Research & Development (2016 - 2025)

Historic Research & Development for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $2.5 billion.

  • Pfizer's Research & Development fell 200.15% to $2.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.8 billion, marking a year-over-year decrease of 729.11%. This contributed to the annual value of $10.8 billion for FY2024, which is 133.91% up from last year.
  • As of Q3 2025, Pfizer's Research & Development stood at $2.5 billion, which was down 200.15% from $2.5 billion recorded in Q2 2025.
  • Pfizer's Research & Development's 5-year high stood at $2.8 billion during Q3 2022, with a 5-year trough of $2.0 billion in Q2 2021.
  • Over the past 5 years, Pfizer's median Research & Development value was $2.6 billion (recorded in 2024), while the average stood at $2.5 billion.
  • In the last 5 years, Pfizer's Research & Development skyrocketed by 2572.58% in 2022 and then crashed by 1163.26% in 2025.
  • Pfizer's Research & Development (Quarter) stood at $2.7 billion in 2021, then rose by 0.56% to $2.7 billion in 2022, then rose by 4.41% to $2.8 billion in 2023, then fell by 7.71% to $2.6 billion in 2024, then fell by 2.0% to $2.5 billion in 2025.
  • Its Research & Development stands at $2.5 billion for Q3 2025, versus $2.5 billion for Q2 2025 and $2.2 billion for Q1 2025.